We have a suspicion that you are an automated web bot software, not a real user. To keep our site fast for other users, we have slowed down this page. The slowdown will gradually disappear. If you think this is a mistake, please contact us at genome-www@soe.ucsc.edu. Also note that all data for hgGeneGraph can be obtained through our public MySQL server and all our software source code is available and can be installed locally onto your own computer. If you are unsure how to use these resources, do not hesitate to contact us.
UCSC Genome Browser Gene Interaction Graph
Gene interactions and pathways from curated databases and text-mining

◀ Back to NOS1

EDN2 — NOS1

Text-mined interactions from Literome

Barton et al., J Am Soc Nephrol 2000 (Glomerulosclerosis, Focal Segmental...) : Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension : mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and Glomerulosclerosis
Zhan et al., Sheng li ke xue jin zhan [Progress in physiology] 2000 (Cardiomyopathy, Hypertrophic) : Angiotensin II ( AII ), endothelin-1 (ET-1) and norepinephrine ( NE ) can inhibit NOS activity and NO production, and induce hypertrophic response in cultured neonatal rat cardiomyocytes ; these effects of AII, ET-1 and NE are mediated respectively by AII receptor, ETA receptor and alpha 1-adrenergic receptor ; these effects of AII and ET-1 are mediated by PTX-sensitive G protein, while the effects of NE are mediated by PTX-insensitive G protein
Verma et al., J Surg Res 2004 (Anoxia) : In some experiments, the effects of endothelin ( ET ) receptor blockade ( with bosentan ) and nitric oxide synthase (NOS) inhibition ( with L-NAME ) on pravastatin mediated cardioprotection were evaluated
Ohlstein et al., J Neurosurg 1992 : An l-arginine analog inhibitor of nitric oxide synthase , L-NG-monomethyl arginine ( L-NMMA, 200 microM ), did not significantly affect basal immunoreactive endothelin levels
Novella et al., Eur J Cardiothorac Surg 2007 (Cardiovascular Diseases) : No change in the AVP response was produced by endothelium removal, exposure to the NO precursor ( 3 x 10 ( -4 ) M L-arginine ), inhibition of nitric oxide ( NO ) synthase ( 3 x 10 ( -5 ) M L-NAME ) or soluble guanylate cyclase ( 3 x 10 ( -6 ) M 1H- [ 1,2,4 ] oxadiazol [ 4,3,-alpha ] quinoxalin-1-one ( ODQ ) ), removal of the superoxide anion ( 100 U/ml superoxide dismutase ( SOD ) plus 1200 U/ml catalase ) or hydroxyl radical ( 10 ( -4 ) M deferoxamine ), or specific alpha1 - ( 10 ( -6 ) M prazosin ) or endothelin ( 10 ( -5 ) M bosentan ) receptor antagonism
Franchi et al., Proc Natl Acad Sci U S A 1994 : Cholinergic stimulation of vascular endothelin activates NO synthase (NOS) , leading to generation of NO from arginine
Lin et al., Eur J Endocrinol 1998 : Role of nitric oxide synthase in release of endothelin from cultured human endometrial cells